Opinion: Diversity in the biopharma industry makes dollars and sense
Biotech CEOs who want to continue receiving investments from some of the largest players in the financial services sector should hear and heed their messages about diversity.
When the European Union made a fresh push for diversity quotas on corporate boards last year, many market watchers dismissed the move as political correctness run amok. The U.S. financial sector would never go along, they predicted, as Wall Street has never been a place for social experiments.
It is turning out that the business case for diversity is proving too powerful to dismiss. A series of recent studies examining diversity and financial performance have fueled growing insistence among big-name private equity firms, pension funds, and money
